Have a feature idea you'd love to see implemented?
Let us know!
OMGA Omega Therapeutics Inc
Price (delayed)
$0.776
Market cap
$42.96M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.32
Enterprise value
$140.72M
Highlights
The company's gross profit has surged by 185% YoY and by 28% QoQ
The revenue has soared by 185% year-on-year and by 28% since the previous quarter
The equity has dropped by 85% year-on-year and by 56% since the previous quarter
Omega Therapeutics's quick ratio has plunged by 62% YoY and by 30% from the previous quarter
Key stats
What are the main financial stats of OMGA
Market
Valuations
Earnings
Shares outstanding
55.37M
Market cap
$42.96M
Enterprise value
$140.72M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.71
Price to sales (P/S)
5.29
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
17.38
Revenue
$8.1M
EBIT
-$70.77M
EBITDA
-$63.46M
Free cash flow
-$56.99M
Per share
Balance sheet
Liquidity
EPS
-$1.32
Free cash flow per share
-$1.03
Book value per share
$0.21
Revenue per share
$0.15
TBVPS
$2.77
Total assets
$152.73M
Total liabilities
$141.18M
Debt
$128.13M
Equity
$11.54M
Working capital
$14.78M
Debt to equity
11.1
Current ratio
1.61
Quick ratio
1.28
Net debt/EBITDA
-1.54
Margins
Efficiency
Dividend
EBITDA margin
-783.9%
Gross margin
100%
Net margin
-902.9%
Operating margin
-916%
Return on assets
-41.2%
Return on equity
-213.1%
Return on invested capital
-31%
Return on capital employed
-55.1%
Return on sales
-874.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
OMGA stock price
How has the Omega Therapeutics stock price performed over time
Intraday
-1.8%
1 week
-23.17%
1 month
-27.48%
1 year
-59.37%
YTD
-74.22%
QTD
-36.39%
Financial performance
How have Omega Therapeutics's revenue and profit performed over time
Revenue
$8.1M
Gross profit
$8.1M
Operating income
-$74.15M
Net income
-$73.09M
Gross margin
100%
Net margin
-902.9%
The company's gross profit has surged by 185% YoY and by 28% QoQ
The revenue has soared by 185% year-on-year and by 28% since the previous quarter
The net margin has surged by 76% year-on-year and by 28% since the previous quarter
The company's operating margin has surged by 76% YoY and by 28% QoQ
Growth
What is Omega Therapeutics's growth rate over time
Valuation
What is Omega Therapeutics stock price valuation
P/E
N/A
P/B
3.71
P/S
5.29
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
17.38
The EPS has grown by 37% YoY and by 7% from the previous quarter
The equity has dropped by 85% year-on-year and by 56% since the previous quarter
The stock's price to book (P/B) is 18% less than its last 4 quarters average of 4.5
The revenue has soared by 185% year-on-year and by 28% since the previous quarter
The price to sales (P/S) is 82% less than the last 4 quarters average of 29.9
Efficiency
How efficient is Omega Therapeutics business performance
OMGA's ROE has plunged by 98% YoY and by 36% from the previous quarter
The ROS has soared by 77% YoY and by 28% from the previous quarter
The ROIC has soared by 58% YoY and by 6% from the previous quarter
OMGA's return on assets is up by 29% year-on-year
Dividends
What is OMGA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for OMGA.
Financial health
How did Omega Therapeutics financials performed over time
The total assets is 8% greater than the total liabilities
Omega Therapeutics's quick ratio has plunged by 62% YoY and by 30% from the previous quarter
Omega Therapeutics's current ratio has plunged by 58% YoY and by 26% from the previous quarter
OMGA's debt to equity has surged by 130% since the previous quarter
The equity has dropped by 85% year-on-year and by 56% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.